Detalles de la búsqueda
1.
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Biochem Biophys Res Commun
; 431(2): 117-23, 2013 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-23318177
2.
Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.
Invest New Drugs
; 31(3): 587-98, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23179339
3.
Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance.
BMC Cancer
; 13: 374, 2013 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23919498
4.
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.
BMC Cancer
; 12: 318, 2012 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22838736
5.
High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation.
Mol Cell Proteomics
; 9(1): 178-83, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19864249
6.
Novel activity of acriflavine against colorectal cancer tumor cells.
Cancer Sci
; 102(12): 2206-13, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21910782
7.
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system.
Int J Cancer
; 124(6): 1463-9, 2009 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19089926
8.
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
J Nat Prod
; 72(11): 1969-74, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19894733
9.
Image-based screening for the identification of novel proteasome inhibitors.
J Biomol Screen
; 12(2): 203-10, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17208922
10.
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Biochem Pharmacol
; 73(1): 25-33, 2007 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17026967
11.
Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
Drug Des Devel Ther
; 11: 1335-1351, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28496304
12.
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
J Biomol Screen
; 11(5): 457-68, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16928983
13.
Screening of an annotated compound library for drug activity in a resistant myeloma cell line.
Cancer Chemother Pharmacol
; 58(6): 749-58, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16528529
14.
Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.
Anticancer Res
; 26(6B): 4125-9, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17201123
15.
AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Biochem Pharmacol
; 87(2): 284-91, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24200998
16.
Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.
Nat Commun
; 5: 3295, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24548894
17.
Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia.
Anticancer Res
; 32(8): 3125-36, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22843883
18.
Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties.
Chem Biol Drug Des
; 78(4): 547-57, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21726416
19.
Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.
Biochem Pharmacol
; 82(2): 139-47, 2011 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21531212
20.
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
Leuk Lymphoma
; 49(12): 2333-43, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19052982